-+ 0.00%
-+ 0.00%
-+ 0.00%

*Arcturus Therapeutics: ARCT-810 Generally Safe and Well Tolerated, Demonstrating Encouraging Activity Across Key Urea Cycle Biomarkers in Ongoing Phase 2 Study >ARCT

Dow Jones·09/23/2026 20:06:00

Please log in to view news